<DOC>
	<DOCNO>NCT01578720</DOCNO>
	<brief_summary>The purpose study assess efficacy safety intravitreal injection aflibercept treatment Choroidal Neovascularization ( CNV ) secondary presume ocular histoplasmosis syndrome ( POHS ) .</brief_summary>
	<brief_title>Intravitreal Aflibercept Injection ( IAI ) Presumed Ocular Histoplasmosis Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Histoplasmosis</mesh_term>
	<criteria>CNV le 1 year duration due presume ocular histoplasmosis Ability provide write informed consent comply study assessment full duration study Age 21 year old Subfoveal juxtafoveal CNV lesion le 5400um diameter Best correct visual acuity 20/25 20/400 Birth control therapy female childbearing age CNV due presume ocular histoplasmosis great 1 year Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch A recent history smoking ( within 1 year study enrollment ) Prior treatment intravitreal aflibercept injection Any condition investigator believe would pose significant hazard subject investigational therapy initiate Uncontrolled glaucoma study eye ( define IOP great equal 30 mmHg despite treatment antiglaucoma medication ) History cerebral vascular accident , myocardial infarction , transient ischemic attack within 3 month study enrollment Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye Presence significant subfoveal fibrosis atrophy Intraocular surgery ( include cataract surgery ) study eye within 2 month enrollment Active intraocular inflammation ( grade trace ) study eye History allergy fluorescein , ICG iodine , amendable treatment Any concurrent intraocular condition study eye ( e.g. , cataract diabetic retinopathy ) , opinion investigator , could either Require medical surgical intervention 12 month study period prevent treat visual loss might result condition , If allow progress untreated , could likely contribute loss least 2 snellen equivalent line BCVA 12 month study period Prior/Concomitant Treatment : Panretinal photocoagulation treatment Previous intraocular steroid PDT within 3 month Previous participation study investigational drug within 30 day precede Day 0 ( exclude vitamin mineral ) Previous treatment intravitreally ( either eye ) intravenously administer Avastin ( bevacizumab ) within 60 day Previous use Macugen Lucentis study eye within 60 day Prior submacular vitreous surgery</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>